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 INTRODUCTION 
Although the pathophysiological mechanisms are not well –defined, the liver-
lung interaction has been well recognized since the nineteenth century1. It seems 
that the former has a crucial role in the control of the hemodynamics of the 
latter. The range of pulmonary changes associated with liver disease is very 
wide and is divided into structural e.g. the anatomical shunts, and functional e.g. 
intrapulmonary vasodilatation (IPVD). The consequences of these changes also 
have a wide range from pulmonary hypotension, gas exchange abnormality to 
portopulmonary hypertension. Severe hyoxemia associated with liver disease 
had been recognized decades ago.  
 
The term hepatopulmonary syndrome (HPS) was 
suggested by Kennedy and Knudson in the late 
seventies of the last century 2. 
HPS is defined as a functional pulmonary 
insufficiency associated with liver disease in the 
absence of intrinsic cardiopulmonary pathology. It 
is a triad of liver disease and/or portal 
hypertension, severe hypoxemia and reversible 
IPVD. This IPVD is predominantly seen in the 
lower two thirds of the lungs 
Patients with liver cirrhosis have 
hyperdynamic circulation and hyperventilation. In 
spite of this fact mild hypoxemia is seen in 70% 
of these patients3. The presence of ascites-which 
mechanically jeopardizes breathing-, hydrothorax 
and true pulmonary arterovenous shunt may 
contribute to this mild hypoxemia. IPVD, the 
structural hallmark of the HPS is the master of the 
low pulmonary vascular resistance and hence the 
reduced pulmonary arterial pressure 
characteristically observed in this disease. 
The importance of this serious syndrome relates to 
the fact that a big group of doctors are not aware 
of this syndrome, despite being not uncommon 
among patients with liver disease. This leads to an 
under estimation of the problem and consequently 
to potential mismanagement of these patients. 
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HPS is reported to affects around 10% of patients 
with liver disease and is present in 17.5% of 
cirrhotics, 13.3% of those with non-cirrhotic 
portal fibrosis, 10% with extrahepatic portal vein 
obstruction and in 20% of patients going for liver 
transplantation. Adult age groups, sex distribution 
and duration of symptoms were not different in 
patients with HPS4, 5 
It affects 2-4% of children with liver 
disease, with a range of 0.5% in those with portal 
vein thrombosis to 20% in biliary atresia and 
polysplenia syndrome. The syndrome is reported 
to affect children as young as 6 months of age 6, 7. 
HPS can affect patients with a wide spectrum of 
liver diseases including viral and non-viral 
hepatitis, granulomatous liver disease including 
sarcoidosis, hepatocellular carcinoma, inferior 
vena cava (posthepatic) obstruction, Budd-Chiari 
syndrome and is reported in patients with non 
cirrhotic portal hypertension and periportal 
fibrosis. HPS due to schistosomaisis was first 
reported in 1997. Pulmonary abnormalities and 
especially HPS are described in association with 
celiac disease and nodular regenerative 
hyperplasia8-13. 
CLINICAL FEATURES 
Patients with HPS typically present with 
symptoms and signs of acute or chronic liver 
disease irrespective of its etiology. Clubbing, 
cynosis, spider naevi and esophageal varices are 
thought to be the best predictive clinical markers 
for the syndrome14. The characteristic clinical 
feature of the syndrome is dyspnea (platypnea) 
when the patient adopts the sitting or standing 
position which improves with recumbency. This is 
accompanied by reduction in oxygen saturation of 
hemoglobin (orthodeoxia). The appearance of 
platypnea and orthodeoxia- which are not 
pathognomonic of the disease- 15, 16 in the absence 
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of cardiopulmonary disease should alert the 
treating team to the onset of the HPS. Dyspnea is 
seen in around 20% of patients with liver disease 
and is usually misattributed to cardiac causes or to 
the mechanical effect of ascites17.  
 Although HPS is reported to be more common in 
patients who have portal hypertension, no 
significant relationship was found between it and 
splenomegaly, ascites, edema, jaundice, oliguria, 
collateral veins  or the etiology of the liver 
disease. 18, 14    
 
Neither the nature nor the Childs-Pugh 
classification of the liver disease has an impact on 
the development of the HPS. In fact HPS may 
develop despite stable liver function.3.  
 
 
       
 
Some patients with intrapulmonary vascular 
dilatations may not develop severe hypoxemia 
and is referred to as intrapulmonary vascular 
dilatation syndrome (IPVDS) or sub-clinical HPS. 
However, stressful conditions- which are 
associated with hyerdynamic circulation and short 
transit time for the blood in the pulmonary bed 
like exercise and pregnancy- may precipitate or 
uncover HPS in these patients.19  
 
HPS is an indication for liver transplantation and 
at the same time it is an independent risk factor 
for morbidity and mortality in patients undergoing 
liver transplantation for other reasons3. 
MECHANISMS OF HYPOXEMIA 
Patients with liver cirrhosis commonly have 
hyperdynamic circulation with reduced peripheral 
resistance and systemic hypotension. The cardiac 
output may reach seven liters per minute. About 
20% to 70% of this is conducted by the IPVD. 
The IPVD results from precapillary and capillary 
pulmonary vascular dilatations. These vessels 
may reach 500 µm in diameter leading to 
functional right-to-left intrapulmonary shunting, 
though there is no true anatomic shunt. The 
compensatory tachycardia associated with 
systemic hypotension in these patients result in a 
short transit time for the blood in the lungs. When 
a normal person breathes room air, the O2 drive- 
in the presence of an adequate transit time- is 
enough to oxygenate the red blood cells at the 
centre of the normal pulmonary vessels (Fig. 1). 
On the other hand the oxygen drive in patients 
with the HPS is short of oxygenating the red 
blood cells at the centre of the stream in the 
dilated capillaries (Fig.2). 
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This is further aggravated by the short transit time 
which does not provide the red blood cells with 
enough time in contact to the alveoli to acquire 
good amount of oxygen. As the vascular 
abnormalities predominate in the middle and 
lower lung fields, ‘when such a patient is in the 
upright position a disproportionately larger 
amount of the blood in the pulmonary circulation 
preferentially- aided by  
 
gravity- flows to the dilated vessels in the 
hypoventilated lung bases. This further enhances 
ventilation-perfusion impairment leading to 
platypnea and orthodeoxia. Unlike what occurs in 
true anatomical shunts, supplemental oxygen 
provides enough driving pressure to overcome the 
relative diffusion defect in HPS (fig.3)’3. 
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The existence of normal O2 tension in some 
patients who have IPVD shadows this dilatation -
leading to ventilation/perfusion impairment- as 
the sole cause for the severe hypoxemia seen in 
patients with HPS. Probably some other unknown 
factors play a role in that.  
 
PATHOGENESIS 
Beside patent airway and vascular bed a normal 
pulmonary vascular tone is mandatory for holding 
adequate ventilation / perfusion equation that 
maintain normal oxygenation. Disturbance of this 
tone either by elevation leading to 
portopulmonary hypertension or by reduction 
causing IPVD and HPS will lead to hypoxemia. 
The cause of the IPVD which is the structural hall 
mark of the HPS is ill defined. The disturbed 
balance between the pulmonary vasodilators and 
vasoconstrictors is thought of as the corner stone 
in the pathogenesis of this syndrome. Three main 
theories were thought to be behind this 
vasodilatation. The first one is   the presence of 
high level of circulating pulmonary vasodilators 
either due to their over production or under 
removal by the diseased liver or they may bypass 
the liver through the collaterals in patients with 
portal hypertension or in operation shunts 20.  
 
The second one is that the damaged liver leads to 
the inhibition of an unknown circulating 
vasoconstrictive substance or the reduction of 
other known pulmonary vasoconstrictors in the 
circulation as the principle cause for the 
dilatation. The third theory has been related to 
possible changes in the sensitivity or number of 
pulmonary receptors of these vasoactive factors. 
Some authors believe that activation of 
neurohumoral homoeostatic systems, like the 
renin-angiotensin-aldosterone system, the 
sympathetic nervous system and the 
hypothalamic/neuropituitary release of 
vasopressin may contribute significantly to the 
circulatory dysfunction seen in cirrhotics 21-24.   
 
Local vasoconstriction in hypo ventilated areas in 
the lung in order to divert the blood to well 
ventilated lung fields is an essential response to 
hypoxia. Impairment of this reaction may also 
contribute to the development of the HPS in these 
patients25.  
Postulations about the exact mediator/s of IPVD 
in the HPS are many.  No single factor could 
explain the whole picture in all patients. However, 
a large number of possible substances in this 
category are under study. An ill defined mediator 
is still part of the on going research and treatment 
3. Other possible mediators include carbon 
monoxide, tumor necrosis factor alpha, 
interleukins, endotheline-1(ET-1), prostaglandins, 
vasoactive intestinal peptide, calcitonin, glucagon, 
substance P, atrial natriuretic factor, platelet-
activating factor and endocannabinoids. Recently 
a lot of research work have focused especially on 
potent vasodilating substances, such as calcitonin 
gene-related peptide, adrenomedullin and nitric 
oxide (NO)26 In addition, vascular endothelial 
growth factor (VEGF) is found to stimulate 
angiogenesis and the development of 
portosystemic collaterals. The blockade of this 
VEGF receptor-2 has been shown to inhibit this 
process27. 
 
NO has been proposed to be the key factor 
modulating the hemodynamic changes seen in 
HPS. 
Investigations had shown high levels of exhaled 
NO in these patients which correlate significantly 
with disturbances in alveolo/arterial O2 gradient 
and ventilation/ perfusion equation. These 
disturbances and the equation return to normal 
after liver transplantation where exhaled NO level 
also become normal. Taken together this further 
reinforces the theory of the effect of NO in the 
pathogenesis of the syndrome28.  
NO is a potent vasodilator that exerts a range of 
physiological and pathophysiological effects. It is 
a labile, highly reactive, diffusible gas that is 
synthesized mainly in the vascular endothelium 
from L-arginine by NO synthase. Three isoforms 
of NO have been identified: inducible NO, 
constitutive endothelial NO, and neuronal NO29. 
Endothelin 1, by increasing endothelial nitric 
oxide synthase activity significantly contributes to 
the increased levels of NO found in patients with 
HPS.30  
This could be explained by the fact that ‘there is 
an increased level of endothelin 1 in patients with 
portal hypertension possibly due to shear stress in 
endothelial cells caused by hyperkinetic 
circulation and also during hepatic injury.’3 This 
is associated with increased expression of 
endothelin-1 receptors alpha and beta (ETRA & 
ETRB) in the lung and hence the effect of ET-1 




resulting in wide spread IPVD, substantial 
disturbances in the ventilation / perfusion 
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equation , widening of alveolar/arterial O2 
gradient  and leading to significant hypoxemia.31   
DIAGNOSIS 
Diagnosis of liver disease and exclusion of 
intrinsic cardiopulmonary disease has to be 
performed by the conventional methods. 
Hypoxemia and IPVD have to be proved.  
Determination of arterial oxygen saturation in the 
supine and upright position by using pulse 
oxymeter while the patients are breathing room air 
is a simple, non-invasive and useful screening test 
for identifying the majority of patients with HPS32, 
33    
Arterial PO2< 70 mmHg and alveolar/arterial O2   
gradient > 30 mmHg and their sum, are the most 
valuable negative and positive predictive values in 
these patients14  
It was reported that the positive predictive value 
for hepatopulmonary syndrome is about 30% for 
alveolar/arterial O2   gradient above 20 mm Hg but 
100 % for arterial PO2below 65 mm Hg when the 
patient is breathing room air34  
 
Routine investigations 
Complete blood count, liver function test, 
electrolytes and chest -x-ray may all be normal 
and are not helpful in the diagnosis of HPS. 
Determination of NO level is done by measuring 
its level in the exhaled air. This may represent a 
crude measure of gas exchange abnormalities in 
patients with liver disease. 
The chest-X-ray may be normal or show the 
common findings seen in patients with liver 
disease. However, ‘the characteristic appearance 
of increased bibasilar nodular or reticulonodular 
opacities representing dilated interstitial and 
pulmonary vascular bed in the clinical setting of 
liver dysfunction and hypoxemia highly suggests 
the presence of the HP’3.  
The finding of normal chest -X-ray and 
pulmonary functional tests in the presence of 
severe hypoxemia is suggestive of 
intrapulmonary vascular dilatation or 
arteriovenous shunt. 
Unlike normal persons and patients with liver 
cirrhosis without severe hypoxemia; patients 
with HPS characteristically have radiological 
changes especially in the lower lung zones on 
CT.35 Thorax high resolution CT may be 
helpful in the diagnosis of HPS by excluding 
pulmonary fibrosis and other interstitial lung 
diseases and demonstrating the dilated 
peripheral pulmonary vessels or increased 
pulmonary artery to bronchus ratios in 
patients with liver disease and hypoxemia36 
 
Lung perfusion scans may be a useful test to 
exclude non-vascular causes of hypoxemia and it 
is helpful in semi-quantification of the severity of  
IPVD especially in follow up of patients with 
severe hypoxemia37. 
 
Assessment of gas exchange 
 Severe hypoxemia (PO2 <60 mmHg) with 
alveolar/arterial O2 gradient of >15mmHg while 
breathing room air is the physiological hallmark 
for HPS. Because of hyperventilation, oxygen 
tension if >65mmHG while the patient is 
breathing room air is not a good measure of 
pulmonary function in patients with HPS.  Instead 
alveolar/arterial oxygen gradient is found to 
correlate well with lung dysfunction 38. An 
increase in the alveolar/ arterial oxygen gradient 
by > 4 mmHg when the patient adopts sitting or 
upright posture from recumbence is almost 
diagnostic of the HPS. Failure to improve PO2 
with supplemental 100% O2 inspiration usually 
indicate the presence of true arteriovenous shunts, 
sever type 1 or type 2 HPS.  
 
Special investigations 
Imaging techniques are mandatory for confirming 
the diagnosis, classification and grading the 
severity of IPVD. Commonly used ones include: 
Contrast-enhanced echocardiography, radio-
labeled macro-aggregated albumin scanning and 
pulmonary arteriography. 
Contrast-enhanced transoesophageal 
echocardiography (CTEE) although semi-
invasive, is more sensitive in detecting IPVD in 
the early stages of hepatic insufficiency and has a 
better correlation with gas-exchange 
abnormalities than Contrast-enhanced 
TransThoracic Echocardiography CTTE 39.  
 ‘Indocyanine green dye or agitated saline that 
provides a stream of micro-bubbles 60 to 90 
microns in diameter are usually used in this test, 
as both of them normally opacify only the right 
heart chambers. They are trapped and filtered by 
the finer (8 microns) pulmonary capillary bed and 
therefore do not appear in the left side of the heart 
in normal lungs (Fig 1 A). However, in the 
presence of an IPVD or intracardiac right-to-left 
shunt, these items opacify the left heart chambers 
(Fig 1 B) either by traversing the lung in the 
former condition or going directly through the 
shunt in the latter’3. In intracardiac right-to-left 
shunts these bubbles appear in the left heart in 3 
heartbeats after they appear in the right heart 
while in IPVD and intrapulmonary shunts these 
bubbles appear in 4–6 heart beats.40 This timing is 
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crucial for the differentiation between the two 
conditions, in addition the cause of the 
intracardiac left to right shunt is usually 
evident by the trans esophageal echo. 
However, it will not differentiate between IPVD 
and intrapulmonary shunts and will not quantitate 
the amount of the shunt.  By detecting localized 
major IPVDs, CTEE will guide the decision for 
surgical or embolic intervention therapy.  
 
Figure 1A Microbubbles in right heart chambers in   




      
 
  Figure 1B Microbubbles in left heart chambers in  





Macro aggregated albumin has large molecule 
exceeding 20 —25 microns in diameter which 
will not normally traverse the normal pulmonary 
capillary bed and when this albumin is radio-
labeled with technetium 99m a traceable 
compound is formed. The appearance of 
radioactivity over the kidneys or brain after 
injecting this substance intravenously indicates 
significant passage of these macro-aggregated 
particles through an intrapulmonary vasodilatation 
or an intracardiac shunt. The advantage of this test 
over the CTEE is its ability to quantify the 
magnitude of the IPVD or shunt.  This is 
estimated by calculating the ratio of systemic to 
total body activity of the radionuclide 41. 
Pulmonary arteriography 
 
This is an invasive procedure and hence it is 
reserved for selected cases especially those with 
poor response to O2. Depending on angiographic 
picture HPS is divided in to two types; type 1 
which is further subdivided into a mild sub-type 
with finely diffuse, spidery infiltrates at the pre-
capillary level close to gas-exchange units of the 
lung and this has a very good response to 
100%O2; and severe sub-type with more 
pronounced vascular dilatation and poor response 
to supplemented O2. Type 2 is characterized by 
localized spongy or blotchy angiographic 
appearance and poor response to O2. This type has 
good response to local spring-coil embolization or 
surgical resection therapy.  
 
TREATMENT 
Unfortunately there is no satisfactory medical 
treatment for the HPS. Finding a treatable 
underlying liver disease is the essential approach 
to the treatment of HPS. 
Recovery of normal hepatic function either 
spontaneously or through treating the underling 
liver disease - if possible - results in resolution of 
the syndrome. On the other hand development of 
pulmonary hypertension in these patients reverses 
the IPVD and consequently leads to initial clinical 
improvement with normalization of oxygen 
saturation before the patient succumbs because of 
this new complication42.  
Simple measures like putting the patient in 
recumbence position and supplying oxygen are 
the first line of therapy. These may ameliorate the 
patients’ symptoms and are suitable means to buy 
time for those going for liver transplantation. 
In attempting to resume the normal pulmonary 
vascular tone and reverse pulmonary 
vasodilatation several medical treatments to 
neutralize or inactivate circulating vasodilators 
were tried. Almitrine bismesylate, indomethacin, 
tamoxifen, somatostatin analogues, 
sympathomimetics, have been used in the 
treatment of HPS with disappointing results 43-47. 
Plasma exchange, hemoperfusion and 
hemodialysis to remove an unknown vasodilator 
were attempted with unsatisfactory outcome17 
Reduction of NO formation using agents like 
methylene blue or blockade of its action 
significantly increases arterial blood pressure and 
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decreases plasma volume and sodium retention 41, 
48-50. 
 
Trials to improve the circulation using vaso-
constrictors like terlipressin combined with 
plasma expanders such as human albumin were 
done with controversial results. Endothelins, 
adenosine antagonists, long-acting 
vasoconstrictors, and antileukotriene drugs may 
prove effectiveness in preventing and treating 
HPS.51  
Transjugular Intrahepatic Portosystemic Shunt 
(TIPS) was thought of initially as treatment for 
HPS especially in patients with non-cirrhotic 
portal hypertension52. However recent data does 
not support that. Nevertheless, TIPS can be done 
safely to treat other complications of portal 
hypertension in patients with HPS and may 
improve levels of PO2 and be feasible, especially 
to gain time as temporal therapy for those waiting 
liver transplantation53. Lobular resection or 
spring-coil embolization therapy may temporary 
help some selected patients with type 2 HPS.  
 
Because of the unsatisfactory results of medical 
therapy for the HPS, liver transplantation remains 
the gold standard treatment for the disease. Severe 
hypoxemia which initially was thought of as 
contraindication for the procedure is considered 
now as an indication for transplantation despite 
the pre-, intra- and postoperative morbidity and 
mortality risk. The perioperative mortality 
remains high (16-38% within 1 year) and appears 
to be greatest in those with more advanced HPS54, 
55. Patients with HPS have increased postoperative 
mortality as well56. Sever hypoxemia (PO2 
<60mmHg) and HPS are considered independent 
risk factors for surgery. The response to liver 
transplantation may not be immediate in fact some 




The course of the disease is typically progressive. 
Although HPS is an independent risk factor for 
morbidity and mortality in patients with liver 
disease; the major morbidity and mortality in 
these patients are those of the liver disease and its 
complication. The mortality rate correlates with 
the pulmonary shunt volume and the degree of 
hypoxemia at room air 57, 58.  The mortality of 
HPS in hospitalized patients is 41% after 2 years6.  
HPS may be complicated by pulmonary 
hypertension, embolic cerebral hemorrhage and 
postoperative hypoxemia.59, 60  
Because of its significant morbidity and mortality 
in patients with liver disease and those who are 
going for transplantation before and after surgery, 
screening and staging the severity of HPS in 
patients going for liver transplantation was 
proposed recently 61, 62 and a scoring system was 
designed to predict the prognosis. However, this 
scoring system needs further verification in large 
population to assess its reliability.63  
Interestingly HPS may show spontaneous clinical 
improvement if the patient develop pulmonary 
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